Trial Condition(s):
Age-related macular degeneration (AMD), Central retinal vein occlusion (CRVO), Diabetic Macular Edema (DME)
Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada
Bayer Identifier:
18498
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Trial Purpose
The primary objective of this study is to measure physician knowledge and understanding of the key safety information contained in the Eylea vial preparation instruction card, the intravitreal injection procedure video, and the product monograph.
Inclusion Criteria
This study will be conducted with retinal specialists and ophthalmologists in Canada who have prescribed and/or administered aflibercept to at least 1 patient in the past 6 months.
Exclusion Criteria
- None applied
Trial Summary
Enrollment Goal
Trial Dates
Phase
Could I receive a placebo?
Products
Accepts Healthy Volunteers
Where to Participate
| Locations | |
|---|---|
Locations Investigative Site Many Locations, Canada | Contact Us: E-mail: [email protected] Phone: Not Available |
Trial Design
Evaluation of Physician Knowledge of Key Safety Information for Eylea in Canada: An Observational Postauthorization Safety Study
Trial Type:
Observational
Intervention Type:
Drug
Trial Purpose:
N/A
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
1
Primary Outcome
- Knowledge and understanding of key information contained in the aflibercept educational materials: the Eylea vial preparation instruction card, the intravitreal injection procedure video, and the product monographThe source of information for the study will be self-reported data collected from physicians using standard questionnaires with closed-ended response choices.Timeframe: Up to 8 weeks after the start of data collection
Secondary Outcome
- Investigation whether physicians have received the educational materialsDescriptive results assessing Number and percentage (%) of physiciansTimeframe: up to 6 month
Additional Information
Copyright © Bayer
Powered by
